Taken together, these findings suggest that pilots holding special issuance waivers for insulin-treated diabetes are not detectably less safe than other airmen with third-class medical certificates and most are able to successfully comply with the FAA's stringent medical certification protocol for insulin treated diabetes.Mills WD, DeJohn CA, Alaziz M. The U.S. experience with waivers for insulin-treated pilots. Aerosp Med Hum Perform. 2017; 88(1):34-41.

The diagnosis of Verruca Vulgaris is usually clinically, but, in certain situations, confirmation of the diagnosis with biopsy is needed. Several dermatological conditions share microscopic features with Verruca Vulgaris; however, the combination of history, dermatological examination, and histological description would confirm the diagnosis. The purpose of this study is to describe pathological conditions that share histological characteristics with verruca Vulgaris. A systematic review of the literature was used in this study. The histological differential diagnosis of verruca Vulgaris was divided into two categories. First, dermatological conditions that characterized by the presence of vacuolated cells; these conditions are Bowen's Disease and Epidermodysplasia Verruciformis. Second, dermatological conditions that show papillomatosis which includes Verrucous Epidermal Nevus, Hyperkeratotic Seborrheic keratosis, and Acanthosis Nigricans Verruciform xanthoma, Confluent and reticulated papillomatosis.

The substantial increased odds of a fatal accident when CAPS was not deployed demonstrated the effectiveness of CAPS at providing protection of occupants during an accident. Injuries were shifted from fatal to serious or minor with the use of CAPS and postcrash fires were significantly reduced. These results suggest that BPRS could play a significant role in the next major advance in improving GA accident survival.Alaziz M, Stolfi A, Olson DM. Cirrus Airframe Parachute System and odds of a fatal accident in Cirrus aircraft crashes. Aerosp Med Hum Perform. 2017; 88(6):556-564.

Background: Preterm birth is a hazard for deleterious short and long-term health outcomes. Cerclage is not a fit for all clinical situations Progesterone clearly plays a role in the maintenance of pregnancy through the relaxant effect of progesterone on myometrial strips in vitro. The progesterone usage in the prevention of preterm birth (PTB) in both singleton and multiple pregnancies has been broadly investigated.Aim of Study: Was to compare the efficacy of vaginal progesterone and cerclage in preventing preterm birth.Patients and Methods: This randomized prospective study was conducted at Al-Hussien University Hospital and Kafr El-Sheikh General Hospital during the period from May 2018 to September 2021. A total 150 pregnant women at high risk of preterm birth who were chosen from the outpatient clinics. They all had singleton pregnancy with gestational age at the first antenatal visit of 12-16 weeks. Additionally, they had history of previous spontaneous preterm labor, and they all presented with sonographic cervical length <25mm in mid trimester.Results: It was observed that in cases who received vaginal progesterone in vaginal progesterone the mean gestational age was (35.68 ±2.63 weeks) while it was (36.14 ±2.11 weeks) in those who underwent cerclage. The mean gestational age improved in the cerclage groups by about 3.92 days. The gestational age at delivery was higher in the cerclage group than that in the progesterone group, but without significant difference (p=0.239). There was statistically significant difference between the both studied groups regarding mean birth weight as it was 2185.9±314.2 in women who received vaginal progesterone compared to 2305.8 ±234.6 in women who underwent cerclage; with p=value=0.025) this may be due to higher percentage of term pregnancy in cerclage group than progesterone one. The mean Apgar score at 1 minute was higher in the cerclage group than that in the progesterone groups (7.79 vs. 7.72). This results showed that the di erence in the mean Apgar score was not statistically significant between the progesterone and the cerclage groups ( p=0.809).

Introduction: Myocarditis and Pericarditis are caused by diverse etiologies, such as infection, toxins, drugs, and vaccines. Myocarditis has been reported previously after smallpox vaccination; however, the incidence was rare. Currently, there are two types of COVID-19 vaccines, mRNA vaccines, and viral vector vaccines. Many cases of myocarditis/Pericarditis after the mRNA COVID-19 vaccine have been reported to the VARES (Vaccine Adverse Event Reporting System). Case Presentation: A 20-year-old male with a history of mild asthma, who previously received two Pfizer covid -19 vaccines, presented to the emergency department with a chief complaint of chest pain two days after receiving a third booster dose of the Moderna vaccine. Troponin and C-Reactive Protein was Elevated, ECG findings revealed acute pericarditis, and MRI showed myocarditis. Echocardiography was normal except for moderate hypokinesis of the septal and inferior left ventricular regional wall segments and trivial pericardial effusion. The patient was admitted for treatment with aspirin, colchicine, metoprolol, and famotidine. His condition was improved, and he was discharged with a follow-up plan. Discussion: So far, most of the cases of Myocarditis/Pericarditis associated with mRNA COVID-19 vaccine were after the second dose; however, not many cases were reported after the booster dose or switching the type of mRNA vaccine. The risk of myocarditis/pericarditis in our patient, with his history of asthma and two doses of Pfizer vaccine, might be increased after switching his booster vaccine to Moderna; nevertheless, the patient still responds well to the treatment without complications. Conclusion: Myocarditis/Pericarditis following receipt of mRNA COVID -19 vaccine is a rare side effect; however, the occurrence of a potentially extremely rare adverse event after an immunization should not lessen the value and the effective benefit of the mRNA COVID-19 vaccine. Further studies are needed to determine the risk of complications following switching between the type of mRNA vaccine.